Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial (STEPS Trial)

NCT06668389 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT06668389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06668389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial (STEPS Trial)
Lead sponsor
The University of Hong Kong
Phase
Phase 4
Overall status
Recruiting
Start date
May 12, 2025
Completion date
December 31, 2026
Enrollment
106 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

congenital heart disease, dapagliflozin (forxiga), pulmonary regurgitation, repaired tetralogy of fallot (rtof), sodium-glucose cotransporter 2 (sglt2) inhibitor